A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Latest Information Update: 11 Dec 2019
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 10 Dec 2019 A population PK analysis was employed to characterize the PK of ruxolitinib using REACH1, Study INCB 18424-251, and COMFORT-I trials; results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 02 Mar 2017 Status changed from active, no longer recruiting to completed.
- 16 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016.